STRATA Skin Sciences Announces First Patients Treated In TheraClearX Clinical Study For Acne
Portfolio Pulse from Happy Mohamed
STRATA Skin Sciences (NASDAQ:SSKN) has announced the treatment of the first six patients in the TheraClearX clinical study for acne. The study aims to evaluate the efficacy and safety of TheraClearX as a stand-alone treatment for mild to moderate acne in 30 healthy subjects aged 12-40.
May 30, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
STRATA Skin Sciences has treated the first patients in the TheraClearX clinical study, which could potentially validate the efficacy and safety of the acne treatment.
The initiation of the TheraClearX clinical study is a positive development for STRATA Skin Sciences, as it could potentially validate the efficacy and safety of the acne treatment. If the study yields positive results, it could lead to increased adoption of the treatment and boost the company's revenues. This news is likely to have a positive short-term impact on SSKN's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100